• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Ptc Therapeutics (NQ: PTCT )

    36.59 +1.11 (+3.13%)
    Streaming Delayed Price Updated: 10:46 AM EDT, Sep 19, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 111,913
    Open 36.36
    Bid (Size) 36.52 (2)
    Ask (Size) 36.65 (1)
    Prev. Close 35.48
    Today's Range 36.28 - 37.07
    52wk Range 17.53 - 40.69
    Shares Outstanding 76,924,170
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    PTC Therapeutics Stock Earns RS Rating Upgrade To 83
    The Relative Strength (RS) Rating for PTC Therapeutics stock climbed into a new percentile Monday, with a rise from 80 to 83. 
    Via Investor's Business Daily
    PTCT Stock Earnings: PTC Therapeutics Misses EPS, Beats Revenue for Q2 2024
    PTCT stock results show that PTC Therapeutics missed analyst estimates for earnings per share but beat on revenue for the second quarter of 2024. 
    Via InvestorPlace

    Performance

    YTD
    +30.49%
    +30.49%
    1 Month
    +6.18%
    +6.18%
    3 Month
    +9.91%
    +9.91%
    6 Month
    +23.99%
    +23.99%
    1 Year
    +42.48%
    +42.48%

    More News

    Read More
    PTC Therapeutics, Inc. (PTCT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
    From Bronstein, Gewirtz & Grossman, LLC
    Via Business Wire
    PTC Therapeutics, Inc. (PTCT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
    From Bronstein, Gewirtz & Grossman, LLC
    Via Business Wire
    Recap: PTC Therapeutics Q4 Earnings
    Via Benzinga
    Earnings Scheduled For February 29, 2024
    Via Benzinga
    Earnings Preview: PTC Therapeutics
    Via Benzinga
    Nike, Accolade And Other Big Stocks Moving Lower In Friday's Pre-Market Session
    Via Benzinga
    PTC Therapeutics Tumbles After European Regulators Reject Its Drug — Again
    Via Investor's Business Daily
    Asana, Clover Health Investments, Hertz Global And Other Big Stocks Moving Higher On Friday
    Via Benzinga
    PTC Therapeutics Says FDA Lifts Clinical Hold On Investigational Study In Patients With Rare Weak Nerve Cell Disorder
    Via Benzinga
    Exposures Product Safety
    The 3 Most Undervalued Biotech Stocks to Buy in June 2024
    Via InvestorPlace
    Why Virios Therapeutics Shares Are Trading Lower By Around 48%? Here Are Other Stocks Moving In Monday's Mid-Day Session
    Via Benzinga
    European Commission Requests Reevaluation Of Opinion On PTC Therapeutics' Duchenne Dystrophy Drug; Pauses Annual Guidance
    Via Benzinga
    Overseas Shipholding, Micron, Squarespace, Incyte And Other Big Stocks Moving Higher On Monday
    Via Benzinga
    PTC Therapeutics Stock Soars As Its Biggest Drug 'Lives To Fight Another Day'
    Via Investor's Business Daily
    12 Health Care Stocks Moving In Monday's Pre-Market Session
    Via Benzinga
    PTC Therapeutics Stock Sees IBD RS Rating Climb To 72
    Via Investor's Business Daily
    PTCT Stock Earnings: PTC Therapeutics Beats EPS, Beats Revenue for Q1 2024
    Via InvestorPlace
    Cooper Companies Reports Upbeat Results, Joins Dell, NetApp, Tidewater And Other Big Stocks Moving Higher On Friday
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    1 of Sarepta Therapeutics' Competitors Just Got Hammered. Will It Help the Stock?
    Via The Motley Fool
    PTC Therapeutics Flashes A Bearish Sign After European Officials Reject DMD Drug
    Via Investor's Business Daily
    PTC Therapeutics To Withdraw Its Conditionally Approved Rare Muscle Disorder Disorder Drug In Europe
    Via Benzinga
    12 Health Care Stocks Moving In Friday's Pre-Market Session
    Via Benzinga
    12 Health Care Stocks Moving In Thursday's After-Market Session
    Via Benzinga
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.